MS onset in childhood: do disease modifying drugs delay long term disability?
17 June 2021
Researchers have investigated how the risk of developing long term disability has changed over the last three decades for people whose MS begins in childhood.
Who gets MS and why?
17 May 2021
The number of people being diagnosed with multiple sclerosis around the world is increasing. In this article we take a look at recent research which investigates who might be more succeptible to multiple sclerosis and why that might be.
Ozanimod (Zeposia) - NICE says no in final decision
13 May 2021
The MS Trust is very disappointed that NICE is unable to recommend ozanimod as an NHS treatment for relapsing remitting MS in England and Wales.
Machine learning identifies new subtypes of MS from MRI scans
13 May 2021
Researchers have identified three new MRI-based subtypes are better able to predict MS activity, disability progression and treatment response than the standard relapsing and progressive subtypes.
Ofatumumab (Kesimpta) approved for relapsing MS in England and Wales
20 April 2021
The MS Trust is delighted that ofatumumab (Kesimpta) has been approved by NICE for people with active relapsing remitting multiple sclerosis.
Under-the-skin injection of Tysabri gets licence in UK and Ireland
16 April 2021
Under-the-skin (subcutaneous) injection of Tysabri (natalizumab) has been approved for UK and Ireland.
Ofatumumab (Kesimpta) gets UK licence for relapsing remitting MS
14 April 2021
The MHRA has granted marketing authorisation for ofatumumab (Kesimpta) for active relapsing remitting MS.
How long does it take for an MS drug to be fully effective?
31 March 2021
Researchers have investigated how long it takes for disease modifying drugs to be fully effective at reducing relapses and slowing progression.
Do medicines reduce fatigue in MS?
8 March 2021
This study compared the effectiveness of amantadine, modafinil and methylphenidate with placebo in people with MS-related fatigue.
Ozanimod (Zeposia) approved for relapsing remitting MS in Scotland
8 February 2021
The MS Trust is delighted that ozanimod (Zeposia) has been approved in Scotland for people with active relapsing remitting multiple sclerosis.
Exercise is good for your brain
3 February 2021
There is more to exercise than physical fitness. This review looks at recent research which shows how exercise has a direct beneficial effect on brain repair processes.
Covid-19 vaccines and MS: Part two
29 January 2021
Following our last interview on the subject of the Covid-19 vaccine and people with MS, we received a lot of follow up questions. To answer some of these, we spoke once again to Professor Alasdair Coles, Consultant Neurologist at Addenbrooke’s hospital.